Qureight is an end-to-end imaging Clinical Research Organization (CRO) that provides enterprise-grade imaging and precision endpoints for clinical trials with a focus on lung and heart disease. It is developing its deep learning AI imaging models to support ongoing clinical trials in the pulmonary hypertension field, where there is demand for robust non-invasive ways to assess disease severity, stratify patients for trials, and detect treatment response over time.
On May 5 Qureight announced that it has established a Scientific Advisory Board (SAB) focused on pulmonary hypertension. Members are Professors Marc Humbert, Steven Nathan, Oksana Shlobin, Vincent Cottin, Ardeschir Ghofrani, Joanna Pepke-Zaba and Luke Howard.
Read more at this link on Biospace